Clinical and Molecular Study of a Gorlin Syndrome Type 1 Case
Abstract
Introduction: Gorlin syndrome (GS) or basal cell nevus syndrome type 1 (BCNS1) is a rare genetic disease belonging to the spectrum of genodermatoses. Here, we present a case with BCNS1 that was caused by haploinsufficiency of PTCH1 gene, which is associated with BCNS1.
Methods: A diagnosis for BCNS1 was clinically set for a 15-year-old female patient who presented with four nevoid skin lesions, four radiolucent osteolytic lesions of the jaws, macrocephaly, unilateral congenital cataracts, strabismus, hypertelorism, and calcification of the falx cerebri. The patient's parents bore no clinical findings indicative of the syndrome.
Results: Whole exome sequencing and array comparative genomic hybridization revealed a heterozygous 2.5 million base pair deletion in the long arm of chromosome 9 (9q22.32q22.33), which encompasses PTCH1 gene among others.
Conclusion: The suggested clinical diagnosis for Gorlin syndrome type 1 was confirmed by genetic analysis. Loss-of-function mutations in PTCH1 gene, including large deletions, are known to promote the formation of neoplasms and craniomaxillofacial phenotype observed in BCNS1 by relieving the inhibition of the sonic hedgehog pathway, which is implicated in cell proliferation.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.